Provided by Tiger Fintech (Singapore) Pte. Ltd.

EVEREST MED

56.200
-0.250-0.44%
Volume:483.80K
Turnover:27.15M
Market Cap:19.89B
PE:-15.90
High:56.850
Open:56.200
Low:55.400
Close:56.450
52wk High:77.550
52wk Low:22.850
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:0.23
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.536
ROE:-23.04%
ROA:-9.09%
PB:4.65
PE(LYR):-15.90
PS:21.45

Loading ...

EVEREST MED (01952) Grants 74,000 Stock Options Under Post-IPO Option Plan

Stock News
·
Oct 02

Everest Medicines Announces New Share Option and Award Grants Under Updated Compensation Plan

Reuters
·
Oct 02

IIgANN 2025: Latest Real-World Studies Confirm NEFECON®'s Sustained Efficacy and Safety in Long-Term Targeted Treatment

Stock News
·
Sep 18

EVEREST MED (01952): NEFECON® to Present 7 Latest Real-World Data Studies at 18th International IgA Nephropathy Symposium

Stock News
·
Sep 15

EVEREST MED (01952) Issues 2.6061 Million Shares Under Pre-IPO Employee Stock Option Plan and Post-IPO Share Award Plan

Stock News
·
Sep 05

Everest Medicines Ltd. Files Next Day Disclosure to HKEX: Announces Increase of 2,607,338 New Shares, Priced at HKD 23.17

Reuters
·
Sep 05

EVEREST MED (01952) Mid-Year Review: Dual "5 Billion Blockbuster" Commercialization Certainty Drives Growth, Global Innovation Value Reaches New Heights

Stock News
·
Aug 30

Stock Track | Everest Medicines Plunges 5% After H1 Results Despite Revenue Growth

Stock Track
·
Aug 29

Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise

MT Newswires Live
·
Aug 29

Everest Medicines Reports 48% Revenue Increase to RMB 446 Million in H1 2025, Driven by NEFECON® and XERAVA® Sales Growth

Reuters
·
Aug 29

Everest Medicines Announces Interim Results for First Half of 2025

THOMSON REUTERS
·
Aug 29

EVEREST MED (01952) Reports Interim Results with Revenue of RMB446 Million, Up 47.96% Year-over-Year

Stock News
·
Aug 29

Everest Medicines H1 Revenue RMB 446.1 Million

THOMSON REUTERS
·
Aug 29

Hong Kong Stock Movement | EVEREST MED (01952) Surges Over 5% in Late Trading as Etrasimod Gains Another International Guideline Recommendation; Company Makes Strategic Investment in TG Therapeutics

Stock News
·
Aug 19

Everest Medicines Subscribes for 15.8 Million ADSs in Global Biotech Firm; Shares Jump 8%

MT Newswires Live
·
Aug 04

BRIEF-Everest Medicines Expands Strategic Investment In I-Mab

Reuters
·
Aug 01

Everest Medicines Expands Strategic Investment in I-Mab

THOMSON REUTERS
·
Aug 01

Everest Medicines Ltd. Expands Stake with $30.9 Million Investment in U.S.-Based Biotech Firm I-Mab

Reuters
·
Aug 01

Everest Medicines - Subscribes for 15.8 Mln Adss of I-Mab for $30.9 Mln

THOMSON REUTERS
·
Aug 01

Everest Medicines Ltd. Completes Private Placement and Top-Up Subscription of Shares Under General Mandate

Reuters
·
Aug 01